Danforth P. Miller
Danforth P. Miller has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Cynthia L. Stevenson
Nektar Therapeutics, 150 Industrial Road, San Carlos, California 94070
1 shared publicationDavid B. Bennett
Nektar Therapeutics, 150 Industrial Road, San Carlos, California 94070
1 shared publicationDavid Lechuga-Ballesteros
Nektar Therapeutics, 150 Industrial Road, San Carlos, California 94070
1 shared publication- David Lechuga-Ballesteros
Pearl Therapeutics, Redwood City, California 94063, United States
1 shared publication - Jeffry G. Weers
Novartis Pharmaceuticals Corporation, San Carlos, CA, United States
1 shared publication John Nakamura
Novartis Pharmaceuticals, San Carlos, California 94070, United States
1 shared publication
Latest Publications
- 3 August 2015
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 12 (8) , 2561
Advances in Respiratory and Nasal Drug Delivery
- 3 August 2015
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 12 (8) , 2561
Advances in Respiratory and Nasal Drug Delivery
- 30 June 2015
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 12 (8) , 2582-2593
Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs
A spray-dried engineered particle formulation, Tobramycin Inhalation Powder (TIP), was designed through rational selection of formulation composition and process parameters. This PulmoSphere powder comprises small, porous particles with a high drug load. As a drug/device combination, TOBI Podhaler enables delivery of high doses of drug per inhalation, a feature critical for dry powder delivery of anti-infectives for treatment of cystic fibrosis. The objective of this work was to characterize TIP on both the particle and molecular levels using multiple orthogonal physical characterization techniques. Differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), electron spectroscopy for chemical analysis (ESCA), and Raman measurements show that a TIP particle consists of two phases: amorphous, glassy tobramycin sulfate with a glass transition temperature of about 100 °C and a gel-phase phospholipid (DSPC) with a gel-to-liquid-crystal transition temperature of about 80 °C. This was by design and constituted a rational formulation approach to provide Tg and Tm values that are well above the temperatures used for long-term storage of TIP. Raman and ESCA data provide support for a core/shell particle architecture of TIP. Particle surfaces are enriched with a porous, hydrophobic coating that reduces cohesive forces, improving powder fluidization and dispersibility. The excellent aerosol dispersibility of TIP enables highly efficient delivery of fine particles to the respiratory tract. Collectively, particle engineering has enabled development of TOBI Podhaler, an approved inhaled drug product that meaningfully reduces the treatment burden to cystic fibrosis patients worldwide.
- 30 June 2015
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 12 (8) , 2582-2593
Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs
A spray-dried engineered particle formulation, Tobramycin Inhalation Powder (TIP), was designed through rational selection of formulation composition and process parameters. This PulmoSphere powder comprises small, porous particles with a high drug load. As a drug/device combination, TOBI Podhaler enables delivery of high doses of drug per inhalation, a feature critical for dry powder delivery of anti-infectives for treatment of cystic fibrosis. The objective of this work was to characterize TIP on both the particle and molecular levels using multiple orthogonal physical characterization techniques. Differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), electron spectroscopy for chemical analysis (ESCA), and Raman measurements show that a TIP particle consists of two phases: amorphous, glassy tobramycin sulfate with a glass transition temperature of about 100 °C and a gel-phase phospholipid (DSPC) with a gel-to-liquid-crystal transition temperature of about 80 °C. This was by design and constituted a rational formulation approach to provide Tg and Tm values that are well above the temperatures used for long-term storage of TIP. Raman and ESCA data provide support for a core/shell particle architecture of TIP. Particle surfaces are enriched with a porous, hydrophobic coating that reduces cohesive forces, improving powder fluidization and dispersibility. The excellent aerosol dispersibility of TIP enables highly efficient delivery of fine particles to the respiratory tract. Collectively, particle engineering has enabled development of TOBI Podhaler, an approved inhaled drug product that meaningfully reduces the treatment burden to cystic fibrosis patients worldwide.
- 1 September 2010
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 99 (9) , 3698-3710
Solid-State Stability of Spray-Dried Insulin Powder for Inhalation: Chemical Kinetics and Structural Relaxation Modeling of Exubera Above and Below the Glass Transition Temperature
- 1 September 2010
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 99 (9) , 3698-3710
Solid-State Stability of Spray-Dried Insulin Powder for Inhalation: Chemical Kinetics and Structural Relaxation Modeling of Exubera Above and Below the Glass Transition Temperature